Relevance of cost-effectiveness analysis to clinicians and policy makers

JAMA

Volumn 298, Issue 2, 2007, Pages 221-224

  Detsky, Allan S ^a,b,c,d   Laupacis, Andreas ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LIFE EXPECTANCY; MEDICAL EDUCATION; MEDICAL PROFESSION; NOTE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ARTICLE; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; MANAGEMENT; MEDICAL TECHNOLOGY; STATISTICAL MODEL;

BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; MODELS, ECONOMIC; POLICY MAKING; QUALITY-ADJUSTED LIFE YEARS;

EID: 34447281815     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.2.221     Document Type: Note

References (15)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
2. Pliskin N, Taylor AK. Chapter 1: general principles: cost-benefit and decision analysis. In: Bunker JP, Barnes BA, Mosteller F, eds. Costs, Risks, and Benefits of Surgery. New York, NY: Oxford University Press; 1977.
3. Abt CC. Chapter 3: the issue of social costs in cost-benefit analysis of surgery. In: Bunker JP, Barnes BA, Mosteller F, eds. Costs, Risks, and Benefits of Surgery. New York, NY: Oxford University Press; 1977.
4. Detsky AS, Naglie IGA. Clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990;113(2):147-154.
5. O'Brien B, Viramontes JL. Willingness to pay: a valid and reliable measure of health state preference? Med Decis Making. 1994;14(3):289-297.
6. Birch S, Gafni A. Cost-effectiveness/utility analysis: do current decision rules lead us to where we want to be? J Health Econ. 1992;11(3):279-296.
7. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med. 1993;37(1):33-40.
8. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146(4):473-481.
9. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: what is a clinically significant gain? J Gen Intern Med. 1994;9(12):702-707.
10. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions: standardizing data on outcomes. N Engl J Med. 1998;339(6):380-386.
11. Kassirer JP, Angell MA. The Journal's policy on cost-effectiveness analyses [editorial]. N Engl J Med. 1994;331(10):669-670.
12. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332(7543):699-703.
13. Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics. 1996;9(6):535-559.
14. Detsky AS. Using cost-effectiveness analysis for formulary decision making. Pharmacoeconomics. 1994;6(4):281-288.
15. Canadian Institute for Health Information. Drug Expenditure in Canada, 1985 to 2006. Ottawa, ON: Canadian Institute for Health Information; 2007.